Looking back into the vmrx archives.....thought this post might generate some comments and perhaps we could get Laura to update us on the status of some of these items:
| Next | Respond | Earnings |
To: philip TESORIERO (1083 )
From: arnold silver Wednesday, Aug 20 1997 11:59AM EST
Reply # of 1237
OK Phil here it is,
Responses
Date: 97-08-20 10:12:04 EDT
From: lam@vimrx.com (Laura)
To: Arnie70@aol.com ('Arnie70@aol.com')
Hello Arnie. Answers to the questions follow. Sorry for the two
day delay, I have been traveling.
Q: Are they looking to build the pipeline? more acquisitions?
A: For the next few months, we are focused on finalizing the
VIMRX/Baxter new cell therapy company and aggressively developing our
existing pipeline. But, if something interesting comes up, we will be
opportunistic. Especially in our target areas of cell therapies, gene
research and therapeutics for cancer and viral diseases. We love doing
deals!
Q:Intensify research on the existing potentials?
A: Yes, the programs in the VIMRX pipeline are moving forward
very quickly. We will file an IND with the FDA on VM201 in early 1998.
VM301 is going to be going into humans within weeks and I will announce
it at that time. We will be making some go/no go decisions on the
hypericin program based on the results of the five studies we unblind in
the 4Q. We will fund all of the programs with the highest potential and
positive results. In VIMRX Genomics Inc., you will see a few scientific
announcements in the near term. If you add in the Baxter events, there
are a number of positive research announcements coming out of our
pipeline in the near future.
Q:Create some new affiliations?
A: Our business development efforts are focused on securing
pharmaceutical/biotechnology partners to generate revenues. (We will
also consider affiliations for the new cell therapies business to help
us to expand research into other areas outside of cancer.) Innovir
provides many opportunities for industry collaboration and we will
announce any partnerships as they are finalized. Bill McIntosh, our new
head of business development, is excellent and has years of
pharmaceutical experience.
Q: Acquire a company w/positive cash flow.
A: Always a possibility I assume. Keep in mind that the
Baxter/VIMRX new company will provide revenues immediately and in time
will be positive. We are still expecting FDA approval of the Isolex
system this year.
Q: How is the Baxter deal going ,and when will it be final ?
A: Everything is going very well! Agreements are scheduled to be
signed in September. Then, we need to send a proxy to request
shareholder and board approval. We are very excited about the formation
of this company and its potential.
Q: It was mentioned on the conference call, you will be
concentrating on shareholder value in the next month .What do you have
scheduled ?
A: Our focus is always on shareholder value - every month! We
are very pleased with the efforts made to reshape this company and
create new prospects for growth. We are well positioned to quickly
develop technologies with significant commercial potential. We are also
ready to deliver income from a number of multiple products and
collaborations.
On the IR front, we are committed to 5-10 institutional/analyst
meetings per month. We are selling our story very aggressively. So
far, the meetings have been very positive and our management team well
received. Research reports are being considered. Many institutions have
told us to try to be patient and focus on finalizing the new company and
moving our clinical programs forward. We agree, but understand how
patient our shareholders have been waiting for a consistent positive
move in the stock. We are focusing on the programs that will best
provide that value to you.
Go VIMRX! Thank you and your board participants for your
support.
PS (Please encourage your fellow investors to ask questions
directly on the conference call. Dick and Dave can discuss many
of these issues directly and they can continue to increase your
confidence on the company's longer term potential.)
looks pretty good to me,
Arnie<<<<<<<<<<<<<<<<<<<<
status VM301?,,,,innovir major pharm alliance???VM201 ind on schedule?????? or has the baxter fiasco put everything on hold...what if isolex doesn't get approved. where is our revenue source?
rhonda |
